Pharmaceuticals Supplements Medical Devices

About Us Careers FAQ All Insights

Privacy Policy Terms of Service

Thai FDA Drug Registration Local Authorized Representative (LAR) & Importer of Record (IOR) Dossier Preparation, ACTD Submissions & Thai Labeling GMP Compliance Consulting Post-Approval Lifecycle Management Pharmacovigilance Government Fee Schedule Pharmaceutical Insights

Thai FDA Supplement Registration Local Importer & Orr.7 Import License GMP Requirements for Supplement Manufacturers Labeling & Health Claims Ingredient Approval & Novel Food Advertising Approval & the Kho Or Permit Supplement Insights

Thai FDA Medical Device Registration Device Classification: AMDD Classes 1-4 Local License Holder & Establishment Licensing Technical File & CSDT Preparation Labeling Requirements: B.E. 2568 (2025) Medical Device Insights

Email WhatsApp (+66) 082.208.2460

Pharmaceutical Regulatory Insights

Analysis of Thai FDA pharmaceutical regulations for foreign drug manufacturers and importers. Articles draw on the Drug Act B.E. 2510 (1967) as amended, ASEAN CTD frameworks, and Thai FDA guidance notifications.

← All Insights

Pharmaceutical Regulatory News

ICH E6(R3) Annex 2 Adopted at Step 4: The Final Good Clinical Practice Standard Is Now in Force ICH completed the E6(R3) revision on June 3, 2026. Clinical trial sponsors in Thailand must now align protocols, monitoring plans, and electronic systems to the final Annex 2 requirements.

US FDA Draft Guidance: Reduced Animal Testing for Oncology Biologics and What It Means for Thailand Dossiers FDA proposed reducing nonclinical animal testing for oncology biologics. If adopted internationally, this lowers the preclinical data burden for cancer drug dossiers submitted to Thai FDA. Comment period closes July 30.

US FDA Finalizes Postapproval Pregnancy Safety Studies Guidance: Thailand Pharmacovigilance Implications FDA finalized its postapproval pregnancy safety study methodology in May 2026. Dual-market registrants in Thailand and the US must align pharmacovigilance programs to both Thai SMP and the new FDA standard.

WHO Greener Pharmaceutical Regulation Initiative: What It Means for Thailand Manufacturing WHO is developing a regulatory white paper on pharmaceutical decarbonization, expected July 2026. Thai manufacturers face rising environmental compliance expectations from global procurement partners and international supply chains.

Thai FDA Enforcement: Ghost Export Operation Targeted for Missing Regulatory Documentation Thai FDA pursued a ghost export scheme involving products shipped without regulatory documentation. What documentation gaps create compliance exposure for manufacturers and exporters in Thailand.

Thailand Ministerial Regulation No. 2 B.E. 2569 (2026): Cannabis Dispensary License Requirements Ministerial Regulation No. 2 restricts cannabis dispensary licenses to health-sector credential holders from May 1, 2026. Supply chain qualification under the new credentialed-access model is now a mandatory compliance step.

WHO Pharmaceuticals Newsletter No. 1/2026: GLP-1 Safety Signals and Thai MAH Obligations WHO's April 2026 newsletter flags new GLP-1 receptor agonist safety signals and ACSoMP recommendations. MAHs in Thailand holding GLP-1 RA, paracetamol, or topiramate registrations must assess labeling and PSUR implications.

Thailand's Ministerial Regulation on Cannabis Extracts: Four Permitted Uses Thailand's cannabis extract regulation took effect April 26, 2026, limiting all THC-containing activity to four lawful purposes and imposing monthly compliance reporting on every permit holder.

PMDA-ATC Pharmacovigilance Seminar 2026: What It Signals for Thailand MAHs PMDA's 2026 APAC pharmacovigilance seminar trained Thai FDA officials on signal detection, RMP development, and real-world data use. What the curriculum signals for upcoming Thai FDA pharmacovigilance expectations.

ICH E2D(R1) Post-Approval Safety Reporting Guideline Now in Global Force ICH E2D(R1) entered implementation globally in March 2026, expanding ICSR obligations to cover digital platforms, social media, and patient support programs. All companies with Thai FDA marketing authorizations must update their pharmacovigilance systems to reflect the expanded source scope.

TGA Permitted Ingredients Determination Effective March 1, 2026 Australia's TGA updated its permitted ingredient list for listed medicines from March 1, 2026. Companies seeking Thai FDA notification-track approvals should check ingredient eligibility against the updated TGA list, as TGA serves as a reference authority for Thai FDA assessments.

Japan Mandates eCTD v4.0 for All New Submissions from April 2026 PMDA became the first major regulator to require eCTD v4.0 submissions, effective April 2026. Companies filing concurrently in Japan and Thailand should understand what this format shift means for dual-market dossier preparation under the bilateral regulatory cooperation framework.

February 15, 2026

ICH M4Q(R2) Draft Guideline: Major CTD Quality Module Revisions Open for Comment ICH opened public consultation on M4Q(R2) in January 2026, proposing significant updates to CTD modules 2.3 and 3 to support digitalization and lifecycle management. When finalized, companies submitting dossiers to Thai FDA will need to restructure their quality sections.

January 21, 2026

11th Thailand-Japan PMDA Regulatory Symposium Convenes in Bangkok Thai FDA and Japan's PMDA met in Bangkok on January 20 to advance bilateral regulatory cooperation, covering regulatory review streamlining, clinical trial activation in Asia, and supply chain management under their 2018 Memorandum of Cooperation.

January 20, 2026

ICH Updates Three Guidelines at Once: E2B(R3), M4Q(R2), and E6(R3) ICH released updated training materials and mapping documents for E2B(R3), M4Q(R2), and E6(R3) in January 2026, providing practical implementation guidance for pharmacovigilance and dossier teams working on Thai FDA submissions aligned with ICH standards.

January 15, 2026

TGA 2026–2027 Compliance Priorities: What They Signal for Thailand Drug Registration TGA published its biennial enforcement priorities for 2026 and 2027, covering prescription medicines, weight-loss products, and falsified goods. Companies using TGA as a reference authority for Thai FDA submissions should review the priority areas that affect their product categories.

January 9, 2026

Pharmaceutical Regulatory Guides

Traditional Medicine Product Registration in Thailand Under the Herbal Products Act Thailand's Herbal Product Act creates a separate registration pathway for traditional medicine products, distinct from the Drug Act framework. This guide covers the classification criteria, dossier requirements, and timelines under Thai FDA's traditional medicine division.

ASEAN Pharmaceutical Harmonization: How It Affects Drug Registration Strategy in Thailand ASEAN pharmaceutical harmonization initiatives are progressively aligning Thailand's drug registration requirements with regional and international standards. This guide explains the key frameworks, their current status, and how they affect registration strategy in Thailand.

ASEAN Common Technical Dossier (ACTD): What It Is and How It Applies to Thai Drug Registration The ACTD dossier is the required submission format for Thai FDA and differs from the ICH CTD used in Western markets. This guide covers Part I through Part IV structure, Thai-language requirements, and the formatting errors that most commonly cause screening failure.

Drug Recall Procedures and Obligations in Thailand Thai FDA requires licensed holders to initiate recalls within defined timeframes when product safety or quality defects are identified. This guide covers recall classification, mandatory notification steps, and the documentation Thai FDA requires for recall closure.

Over-the-Counter Drug Registration in Thailand: Non-Dangerous and Household Remedy Categories Non-dangerous and household remedy drugs follow a simplified registration pathway in Thailand, but qualifying for OTC status requires meeting Thai FDA's category criteria. This guide covers classification rules, dossier requirements, and the approved household remedy list.

Drug Advertising and Promotion Rules in Thailand Thai FDA controls pharmaceutical advertising through a prior approval requirement for all consumer-directed drug advertisements. This guide covers permitted claims, HCP promotion rules, digital channel obligations, and enforcement.

Thailand's National List of Essential Medicines and Government Hospital Procurement Thailand's National List of Essential Medicines determines which drugs qualify for government hospital procurement. This guide covers NLEM listing criteria, procurement mechanisms, and pricing implications for foreign manufacturers seeking government market access.

Clinical Trial Authorization in Thailand: The CSN Process and GCP Requirements Clinical trials in Thailand require authorization through Thai FDA's Clinical Study Notification process before the first patient is enrolled. This guide covers the submission requirements, ethics committee review, and GCP compliance standards.

Bioequivalence Study Requirements for Generic Drug Registration in Thailand Generic drug applications in Thailand require bioequivalence studies demonstrating that the product performs comparably to the Thai FDA-approved comparator. This guide covers study design requirements, acceptable comparator products, and waiver criteria.

Drug Labeling Requirements in Thailand Under the Drug Act Thai FDA mandates specific text, symbols, and language on every drug container and package insert. This guide covers inner container, outer packaging, and package insert requirements, and the labeling failures that most commonly cause screening return.

Biologics and Biosimilar Registration in Thailand Biological products and biosimilars face additional characterization, comparability, and clinical data requirements beyond standard drug registration in Thailand. This guide covers the regulatory pathway, dossier requirements, and post-approval obligations specific to biologics.

Post-Approval Changes in Thailand: When You Need to Notify, Vary, or Re-Register Marketing authorization holders must notify or seek approval from Thai FDA before implementing manufacturing, formulation, or labeling changes. This guide covers the variation types, documentation requirements, and timelines for post-approval change management.

Thailand's Good Distribution Practice (GDP) Requirements for Pharmaceutical Importers Thai FDA GDP requirements govern the storage, handling, and distribution of medicinal products from the import stage through to the dispensing point. This guide covers facility requirements, cold chain obligations, and the documentation standards that support GDP compliance.

Generic Drug Registration in Thailand: Requirements, Bioequivalence, and Timelines Generic drug registration in Thailand follows a structured pathway with distinct dossier requirements, comparator product rules, and bioequivalence data obligations that differ from the new drug registration process.

Thailand's GMP Requirements for Drug Manufacturing Thai FDA must accredit every overseas manufacturing site before a marketing authorization can be issued. This guide covers the GMP accreditation process, certificate validity, scope limitations, and how to avoid clearance failures that stall a registration application.

What Is a Licensed Agent Representative (LAR) and When Does Thailand Require One? Every foreign manufacturer registering a drug in Thailand must appoint a Thai-licensed LAR to hold the marketing authorization. This guide explains the LAR and IOR roles, establishment license requirements, and what to verify before appointing a representative.

Drug Import and Export Licensing in Thailand: A Step-by-Step Overview Every drug imported into Thailand for commercial distribution requires an import license held by a Thai-licensed entity. This guide covers the licensing framework, documentation requirements, and the distinction between import for commercial sale and import for registration purposes.

Thailand's Narcotics and Psychotropic Substances Framework for Pharmaceutical Companies Thailand's narcotics and psychotropic framework imposes licensing, quota, and reporting requirements that go beyond standard drug registration. This guide covers the ONCB authorization process, import controls, and the additional obligations that apply to controlled substances.

Pharmacovigilance Obligations in Thailand: What Drug License Holders Must Report Thai FDA pharmacovigilance obligations apply from the date of marketing authorization and include adverse event reporting, periodic safety reviews, and a maintained pharmacovigilance system that the LAR must operate throughout the product lifecycle.

How Drug Registration Works in Thailand Thai FDA drug registration follows a structured pathway from classification through ACTD dossier review to marketing authorization. Understanding the full process before you start saves months.

Pharmaceutical Regulatory Services

Pharmaceutical Regulatory Overview

Dossier Preparation, ACTD Submissions & Thai Labeling We prepare ACTD dossiers in-house for Thai FDA submission, covering all four parts, Thai-language labeling requirements, and post-submission query management.

Local Authorized Representative & Importer of Record VeroPharma Group holds the establishment licenses required to serve as LAR and IOR, bearing full legal responsibility for your product on the Thai market.

GMP Compliance for Thai FDA Registration We manage GMP accreditation applications for overseas manufacturing sites and maintain currency of certificates throughout the product registration lifecycle.